GENERAL INFORMATION YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries. YUMAB’s integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels. YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization. Newest achievement is the fast track COVID-19 program of YUMAB’s spin-off CORAT Therapeutics from target to patient in 11 months. SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES 1. Fast track discovery of fully human antibodies 2. Immune or patient derived libraries (also from transgenic animals) 3. Antibody lead development (IgG, Fab, scFv, bispecifics, CAR, ADC, …) 4. Antibody engineering (affinity, stability, manufacturability) 5. In silico lead optimization 6. Hybridoma sequencing 7. Humanization, Superhumanization 8. Contract research and development 9. Partnered development | YUMAB is an innovative biotech company developing next-generation therapeutic antibodies for clients and partners worldwide. The YUMAB platform comprises proprietary library technologies including one of the world’s largest human antibody libraries (>10e11), patient derived libraries and immune libraries from many different species. YUMAB integrates all technologies from discovery over engineering and AI enabled lead optimization to achieve highest success-rates to all types of targets, modalities and indications, e.g. for the development of TCRm to pHLA. YUMAB also offer licenses to its antibody technology platforms such as a novel BBB shuttle technology or T cell engagers.
Xiaomo Biotech Limited
Xiaomo Biotech is an expert on RNA biosynthesis. Our green biomanufacturing technology produces highly potent, specific, and cost-effective siRNAs (to kilograms) for various RNAi applications including gene knockdown in mammalian cells, high-throughput RNAi screen and RNAi pesticide. Xiaomo is committed to developing cutting-edge biotech products based on RNA interference (RNAi), a natural process which uses small interfering RNAs (siRNAs) to silence target genes in a precise manner. Xiaomo possesses a revolutionary RNAi platform technology known as the ‘prokaryotic siRNA’ (pro-siRNA) technology. The pro-siRNA technology uses bacteria as siRNA ‘factory’ instead of using chemical synthesis. This unique biomanufacturing method enables cost-effective and environmentally friendly production of highly effective siRNAs on a massive scale. Xiaomo has the capacity to produce siRNAs in gram to kilogram scales using bacterial fermentation. Xiaomo has also developed a customized high-throughput RNAi screen technique to identify potential therapeutic target genes in a disease, that could lead to the development of novel RNAi therapeutics. Currently, Xiaomo is offering various biomanufactured siRNA and RNAi library products to the R&D market. Xiaomo’s R&D efforts focus on developing first-in-class RNA pesticides for important crop pests including fungi, insects and nematodes. The ultimate goal of Xiaomo is to provide effective and affordable RNAi solutions for improving both human health and agricultural health. Xiaomo Biotech (www.xiaomobio.com) was founded at Hong Kong Science Park in 2019. We have recently established R&D and production sites in Shanghai Zhangjiang and Suzhou Kunshan China.
West Pharmaceutical Services
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year. 2023 marks West’s 100-year milestone of innovation and the critical role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com. | West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year. In 2023, West commemorated a century of groundbreaking innovation that has shaped the landscape of healthcare and impacted the lives of patients around the world. This milestone served as a testament to West’s commitment to revolutionize drug delivery and enhance the overall patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com. | West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com.
Wellgem Biopharma
Wellgem Biopharma is a biopharmaceutical CDMO offering process development, GMP supply, and quality control services to clients worldwide. With extensive experience in the biopharmaceutical field, the company covers microbial and mammalian-origin products from preclinical development to commercialization. A fully digital quality system ensures complete product compliance at all stages of program development and commercial operations. Founded in 2021, Wellgem Biopharma is a privately owned company with facilities in Kaunas, Lithuania. The company is expanding rapidly and plans to enter the cell and gene therapy sector
Wales Cymru (Welsh Government)
Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Vipragen Biosciences Private Limited
Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. Additionally, the laboratory has been certified by AAALAC, NABL, and DCGI to support discovery research. Vipragen has deep scientific and research knowledge with a combined experience of over 150 years of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen Biosciences Pvt. Ltd. is a globally recognized Contract Research Organization(CRO) which has been in the industry for more than a decade now and specializing in delivering comprehensive pre-clinical services to Global Drug Discovery companies. We are OECD-GLP certified and AAALAC accredited laboratory with the State-of-the-art Vivarium to carry out safety studies for regulatory submissions. Vipragen has deep scientific and research knowledge of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen, a renowned Contract Research Organization (CRO), offers comprehensive services for global Pharmaceutical, Biopharmaceutical, Chemical, Nutraceutical and Medical Device companies. With over 12 years of experience, Vipragen Biosciences Private Limited is dedicated to delivering quality services. Under the leadership of Dr. Chandrashekaran Siddamadappa, Chairman and Managing Director, Vipragen has emerged as an Integrated Pre-clinical CRO, championing sustainability, integrity, safety and quality. Our state-of-the-art Vivarium holds Global certifications like OECD GLP, AAALAC and NABL, supported by multidisciplinary experts and equipped with 21CFR Part 11 compliance systems and processes. We ensure reliable data adhering to global standards with a focus on customer satisfaction. Our diverse portfolio includes Analytical, Toxicology and Chemistry services tailored to meet stringent regulatory submission requirements across the industries, ensuring compliance and transparency for clients across the industry spectrum.
Vffice Inc
VFFICE is a Microsoft Cloud Solution Partner specializing in Enterprise Software, including ERP, CRM, BI, and Custom Development for the Pharma and Life Sciences Industry. We serve clients globally promoting growth and digital transformation with a dedicated focus on the Microsoft platform and AI. | VFFICE is a Microsoft Cloud Solution Partner delivering innovative, Microsoft‑based enterprise solutions for the Pharma and Life Sciences industry. We enhance traditional ERP with advanced data analytics, automation, and embedded AI to support regulatory compliance, reporting, batch and inventory traceability, quality management, formulation control, LIMS integration, and real‑time financial and operational visibility. Our solutions empower pharmaceutical and life sciences organizations across R&D, drug discovery, diagnostics, biomanufacturing, and distribution to accelerate innovation, improve operational excellence, and drive digital transformation. With deep expertise in ERP, CRM, BI, and custom development on the Microsoft platform, VFFICE serves clients globally, helping them scale with confidence in highly regulated environments.
Vettiva Saúde Animal
Vettiva Animal Health is a biotech startup focused exclusively on Research and Development (R&D) and commercialization of innovative pharmaceuticals derived from Medical Cannabis. It is also the first company to formalizeclinical development of cannabidiol-based veterinary candidate therapies with the Brazilian Ministry of Agriculture, Livestock, and Supply (MAPA).
Veeda Lifesciences
For nearly two decades, Veeda Lifesciences has been a trusted partner in drug development, supporting pharmaceutical, biotech, and specialty healthcare companies in bringing innovative therapies to patients worldwide. Our global presence spans across 9 countries and 26 geographies, allowing us to offer localized expertise while maintaining a broad international reach. By combining scientific excellence, regulatory expertise, and cutting-edge technology, we ensure the execution of efficient, high-quality clinical trials that accelerate the drug development process. A Strategic Partner in Drug Development Veeda Lifesciences partners with innovator companies to navigate the intricate landscape of clinical research and drug development. Our comprehensive suite of services covers: Strategic Consulting: We provide expert guidance in trial design, regulatory pathways, and market access strategies, ensuring seamless progression from preclinical to clinical phases. Regulatory Support: Our regulatory affairs team assists with dossier preparation, regulatory submissions, and interactions with health authorities, streamlining the approval process. Operational Excellence: We offer end-to-end trial management solutions, including site selection, patient recruitment, monitoring, data management, and biostatistical analysis. Expertise Across Multiple Therapeutic Areas With deep domain expertise in key therapeutic areas, Veeda has played a pivotal role in advancing clinical research in: Oncology & Hematology: Our contributions include supporting one of the largest global multiple myeloma trials across 24 countries. By leveraging AI-driven patient recruitment strategies and real-world data, we optimize site selection and accelerate trial timelines. Dermatology: We have successfully executed clinical trials for novel dermatological therapies, addressing conditions such as psoriasis, atopic dermatitis, and skin cancers. Endocrinology & Metabolic Disorders: Veeda has been instrumental in conducting trials for diabetes, obesity, and other endocrine disorders, ensuring the safety and efficacy of new treatment modalities. Other Specialties: Our expertise extends to cardiovascular diseases, infectious diseases, autoimmune disorders, and rare diseases, enabling comprehensive clinical research solutions across various indications. Comprehensive Clinical Development Lifecycle Support Veeda Lifesciences offers integrated solutions across the entire clinical development lifecycle, ensuring scientific rigor, regulatory compliance, and operational efficiency at every stage: Early-Phase Studies: First-in-Human (FIH) and Phase I trials Bioavailability & bioequivalence (BA/BE) studies Pharmacokinetics (PK) and pharmacodynamics (PD) evaluations Adaptive trial designs to optimize early-stage decision-making Late-Stage Clinical Trials: Phase II-IV multi-regional clinical trials (MRCTs) Patient-centric study designs incorporating decentralized trial models Site feasibility assessments and accelerated patient enrollment strategies Global regulatory submissions and post-marketing surveillance Advanced Capabilities and Technology-Driven Approach Our commitment to technological innovation enhances trial efficiency and data integrity through: Bioanalytical Research & Central Lab Services: High-quality analytical testing for small molecules, biologics, and biosimilars, ensuring accurate pharmacokinetic and immunogenicity assessments. Digital Trial Management: AI-powered platforms for real-time data capture, electronic trial management, and remote monitoring, optimizing trial workflows. Patient Engagement Solutions: Digital tools to enhance patient retention, adherence, and real-world evidence generation, improving trial outcomes. Pharmacovigilance & Safety Monitoring: Comprehensive adverse event reporting and risk mitigation strategies, ensuring regulatory compliance and patient safety. Biopharmaceutical Development Expertise Veeda Lifesciences offers a comprehensive suite of services tailored to support the development of biopharmaceuticals, including biologics and biosimilars. Our expertise encompasses non-clinical testing solutions designed to ensure safety, efficacy, and regulatory compliance for complex biological therapies. Key Biopharma Services: Preclinical Research: We conduct rigorous preclinical studies to assess the safety and biological activity of biotherapeutic candidates, providing a solid foundation for clinical development. Bioanalytical Support: Our bioanalytical services include method development, validation, and high-throughput sample analysis, delivering precise data essential for regulatory submissions. Regulatory Consulting: We offer strategic guidance on regulatory pathways for biologics and biosimilars, assisting with dossier preparation and interactions with health authorities to streamline approvals. By integrating these services, Veeda Lifesciences ensures a seamless transition from discovery to market for biopharmaceutical products, upholding the highest standards of scientific integrity and patient safety. Beyond Clinical Trials: Integrated Research Solutions Veeda Lifesciences offers a holistic approach to drug development with a diverse range of research services, including: Preclinical Testing: In vitro and in vivo studies to assess drug safety, efficacy, and toxicity before clinical trials. Regulatory Consulting: Expert navigation of global regulatory landscapes, including US FDA, EMA, MHRA, DCGI, and other health authorities. Medical Writing & Scientific Documentation: Preparation of clinical study reports, investigator brochures, regulatory dossiers, and scientific publications to support regulatory approvals. A Trusted Partner for Advancing Life-Changing Therapies Veeda Lifesciences is committed to upholding the highest standards of scientific integrity, patient-centric research, and global regulatory excellence. Our collaborative approach, coupled with a strong emphasis on quality, innovation, and operational efficiency, makes us the preferred partner for companies seeking to bring transformative therapies to market. For more information, visit: Veeda Lifesciences